Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

679 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink R, van Gerwen B, Féliz L, Abou-Alfa GK, Ross JS, van de Ven M, Rottenberg S, Cuppen E, Chessex AV, Ali SM, Burn TC, Jimenez CR, Ganesan S, Wessels LFA, Jonkers J. Zingg D, et al. Among authors: lutz c. Nature. 2022 Aug;608(7923):609-617. doi: 10.1038/s41586-022-05066-5. Epub 2022 Aug 10. Nature. 2022. PMID: 35948633 Free PMC article. Clinical Trial.
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.
Barazas M, Annunziato S, Pettitt SJ, de Krijger I, Ghezraoui H, Roobol SJ, Lutz C, Frankum J, Song FF, Brough R, Evers B, Gogola E, Bhin J, van de Ven M, van Gent DC, Jacobs JJL, Chapman R, Lord CJ, Jonkers J, Rottenberg S. Barazas M, et al. Among authors: lutz c. Cell Rep. 2018 May 15;23(7):2107-2118. doi: 10.1016/j.celrep.2018.04.046. Cell Rep. 2018. PMID: 29768208 Free PMC article.
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
Annunziato S, de Ruiter JR, Henneman L, Brambillasca CS, Lutz C, Vaillant F, Ferrante F, Drenth AP, van der Burg E, Siteur B, van Gerwen B, de Bruijn R, van Miltenburg MH, Huijbers IJ, van de Ven M, Visvader JE, Lindeman GJ, Wessels LFA, Jonkers J. Annunziato S, et al. Among authors: lutz c. Nat Commun. 2019 Jan 23;10(1):397. doi: 10.1038/s41467-019-08301-2. Nat Commun. 2019. PMID: 30674894 Free PMC article.
In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.
Annunziato S, Lutz C, Henneman L, Bhin J, Wong K, Siteur B, van Gerwen B, de Korte-Grimmerink R, Zafra MP, Schatoff EM, Drenth AP, van der Burg E, Eijkman T, Mukherjee S, Boroviak K, Wessels LF, van de Ven M, Huijbers IJ, Adams DJ, Dow LE, Jonkers J. Annunziato S, et al. Among authors: lutz c. EMBO J. 2020 Mar 2;39(5):e102169. doi: 10.15252/embj.2019102169. Epub 2020 Jan 13. EMBO J. 2020. PMID: 31930530 Free PMC article.
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink R, van Gerwen B, Féliz L, Abou-Alfa GK, Ross JS, van de Ven M, Rottenberg S, Cuppen E, Chessex AV, Ali SM, Burn TC, Jimenez CR, Ganesan S, Wessels LFA, Jonkers J. Zingg D, et al. Among authors: lutz c. Nature. 2022 Sep;609(7929):E13. doi: 10.1038/s41586-022-05287-8. Nature. 2022. PMID: 36050473 Free PMC article. No abstract available.
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.
Zimmerli D, Brambillasca CS, Talens F, Bhin J, Linstra R, Romanens L, Bhattacharya A, Joosten SEP, Da Silva AM, Padrao N, Wellenstein MD, Kersten K, de Boo M, Roorda M, Henneman L, de Bruijn R, Annunziato S, van der Burg E, Drenth AP, Lutz C, Endres T, van de Ven M, Eilers M, Wessels L, de Visser KE, Zwart W, Fehrmann RSN, van Vugt MATM, Jonkers J. Zimmerli D, et al. Among authors: lutz c. Nat Commun. 2022 Nov 2;13(1):6579. doi: 10.1038/s41467-022-34000-6. Nat Commun. 2022. PMID: 36323660 Free PMC article.
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
Ter Brugge P, Moser SC, Bièche I, Kristel P, Ibadioune S, Eeckhoutte A, de Bruijn R, van der Burg E, Lutz C, Annunziato S, de Ruiter J, Masliah Planchon J, Vacher S, Courtois L, El-Botty R, Dahmani A, Montaudon E, Morisset L, Sourd L, Huguet L, Derrien H, Nemati F, Chateau-Joubert S, Larcher T, Salomon A, Decaudin D, Reyal F, Coussy F, Popova T, Wesseling J, Stern MH, Jonkers J, Marangoni E. Ter Brugge P, et al. Among authors: lutz c. Nat Commun. 2023 Apr 7;14(1):1958. doi: 10.1038/s41467-023-37537-2. Nat Commun. 2023. PMID: 37029129 Free PMC article.
A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.
Hutten SJ, de Bruijn R, Lutz C, Badoux M, Eijkman T, Chao X, Ciwinska M, Sheinman M, Messal H, Herencia-Ropero A, Kristel P, Mulder L, van der Waal R, Sanders J, Almekinders MM, Llop-Guevara A, Davies HR, van Haren MJ, Martin NI, Behbod F, Nik-Zainal S, Serra V, van Rheenen J, Lips EH, Wessels LFA; Grand Challenge PRECISION Consortium; Wesseling J, Scheele CLGJ, Jonkers J. Hutten SJ, et al. Among authors: lutz c. Cancer Cell. 2023 May 8;41(5):986-1002.e9. doi: 10.1016/j.ccell.2023.04.002. Epub 2023 Apr 27. Cancer Cell. 2023. PMID: 37116492 Free PMC article.
Rat Models of Hormone Receptor-Positive Breast Cancer.
Nicotra R, Lutz C, Messal HA, Jonkers J. Nicotra R, et al. Among authors: lutz c. J Mammary Gland Biol Neoplasia. 2024 Jun 24;29(1):12. doi: 10.1007/s10911-024-09566-0. J Mammary Gland Biol Neoplasia. 2024. PMID: 38913216 Free PMC article. Review.
Mechanisms that clear mutations drive field cancerization in mammary tissue.
Ciwinska M, Messal HA, Hristova HR, Lutz C, Bornes L, Chalkiadakis T, Harkes R, Langedijk NSM, Hutten SJ, Menezes RX, Jonkers J, Prekovic S; Grand Challenge PRECISION consortium; Simons BD, Scheele CLGJ, van Rheenen J. Ciwinska M, et al. Among authors: lutz c. Nature. 2024 Sep;633(8028):198-206. doi: 10.1038/s41586-024-07882-3. Epub 2024 Sep 4. Nature. 2024. PMID: 39232148 Free PMC article.
679 results